Magnus Harneshaug1,2, Jurate Saltyte Benth3,4,5, Lene Kirkhus3,2,6, Bjorn Henning Gronberg7,8, Sverre Bergh3,9, Siri Rostoft2,10, Marit Slaaen3,2,11. 1. The Research Centre for Age Related Functional Decline and Diseases, Innlandet Hospital Trust, Ottestad, Norway Magnus.Harneshaug@sykehuset-innlandet.no MagnusHarneshaug@gmail.com. 2. Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. 3. The Research Centre for Age Related Functional Decline and Diseases, Innlandet Hospital Trust, Ottestad, Norway. 4. Institute of Clinical Medicine, Campus Ahus, University of Oslo, Oslo, Norway. 5. Health Services Research Unit, Akershus University Hospital, Nordbyhagen, Norway. 6. Department of oncology, Oslo University Hospital, Oslo, Norway. 7. Department of Oncology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway. 8. Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway. 9. Norwegian Advisory Unit on Aging and Health, Vestfold Hospital Trust, Tønsberg, Norway. 10. Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway. 11. The Cancer Unit, Innlandet Hospital Trust, Hamar Hospital, Hamar, Norway.
Abstract
BACKGROUND/AIM: Muscle loss, inflammation, and frailty are prevalent among older cancer patients. We aimed to evaluate whether inflammatory markers could identify muscle loss, and if muscle measures differed between frail and non-frail patients. PATIENTS AND METHODS: A total of 115 patients ≥70 years old with solid tumors were included. Inflammation was measured using the Glasgow Prognostic Score (GPS), which is based on C-reactive protein (CRP) and albumin levels, and CRP alone. Frailty was evaluated using a modified geriatric assessment (mGA) of eight domains affecting older patients' health status. Computed tomography-derived muscle measures were collected at the level of the third lumbar vertebra. RESULTS: Patients with GPS=2 and CRP>27 mg/l exhibited poorer muscle measures compared to patients with lower levels. No associations between mGA-based frailty and muscle mass were found. CONCLUSION: Inflammation has detrimental effects on muscle mass. However, GPS or CRP alone cannot be used to identify muscle loss, and muscle measures were not associated with frailty in this series. Copyright
BACKGROUND/AIM: Muscle loss, inflammation, and frailty are prevalent among older cancerpatients. We aimed to evaluate whether inflammatory markers could identify muscle loss, and if muscle measures differed between frail and non-frail patients. PATIENTS AND METHODS: A total of 115 patients ≥70 years old with solid tumors were included. Inflammation was measured using the Glasgow Prognostic Score (GPS), which is based on C-reactive protein (CRP) and albumin levels, and CRP alone. Frailty was evaluated using a modified geriatric assessment (mGA) of eight domains affecting older patients' health status. Computed tomography-derived muscle measures were collected at the level of the third lumbar vertebra. RESULTS:Patients with GPS=2 and CRP>27 mg/l exhibited poorer muscle measures compared to patients with lower levels. No associations between mGA-based frailty and muscle mass were found. CONCLUSION:Inflammation has detrimental effects on muscle mass. However, GPS or CRP alone cannot be used to identify muscle loss, and muscle measures were not associated with frailty in this series. Copyright
Authors: Matteo Cesari; Stephen B Kritchevsky; Richard N Baumgartner; Hal H Atkinson; Brenda W H J Penninx; Leon Lenchik; Shana L Palla; Walter T Ambrosius; Russell P Tracy; Marco Pahor Journal: Am J Clin Nutr Date: 2005-08 Impact factor: 7.045
Authors: Maria-José Molina-Garrido; Carmen Guillén-Ponce; Borja Manuel Fernández-Félix Journal: J Am Med Dir Assoc Date: 2016-06-07 Impact factor: 4.669
Authors: Vickie E Baracos; Lisa Martin; Murray Korc; Denis C Guttridge; Kenneth C H Fearon Journal: Nat Rev Dis Primers Date: 2018-01-18 Impact factor: 52.329